Advertisement
Advertisement

VERV

VERV logo

Verve Therapeutics Inc

5.46
USD
-0.15
-2.67%
Dec 18, 13:49 UTC -5
Open

Verve Therapeutics Inc Profile

About

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.

Info & Links

CEO

Sekar Kathiresan

Headquarters

201 BROOKLINE AVENUE, SUITE 601
BOSTON, MA 02215, UNITED STATES

Industry

Biotechnology

Sector

Health Technology

Website

www.vervetx.com

Auditor

Ernst & Young LLP

Share holders

--

Employees

255

Verve Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

462.24M

Enterprise Value

303.53M

Enterprise Value/EBITDA(ttm)

-1.30

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

19.82

Price to Book(mrq)

0.95

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-807.65%

Profit Margin(ttm)

-817.56%

Return on Equity(ttm)

-35.23%

Return on Invested Capital(ttm)

-35.40%

Return on Assets(ttm)

-27.65%

Income Statement

Revenue(ttm)

24.40M

Revenue Per Share(ttm)

0.29

Gross Profit(ttm)

24.40M

EBITDA(ttm)3

-233.56M

Net Income Available to Common(ttm)

-197.03M

Diluted EPS(ttm)

-2.46

Share Statistics

Beta (5Y Monthly)

1.71

52-Week Change

-54.54%

S&P 500 52-Week Change

27.89%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

84.66M

Dividend Yield

0.00%

Float4

68.32M

% Held by Insiders

19.30%

% Held by Institutions

97.11%

Balance Sheet

Total Cash(mrq)

539.92M

Total Cash Per Share(mrq)

6.38

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.05%

Quick Ratio(mrq)

13.05%

Book Value Per Share(mrq)

6.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.38

Free Cash Flow(ytd)

-119.20M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement